The FDA has delayed a decision on Praxis Precision Medicines' rare epilepsy dr-g. The dr-g, relutrigine, treats SCN2A and SCN8A encephalopathies. The agency requires three additional months to review new sensitivity analyses. This pushes the decision date back to December 27. Analysts suggest FDA staff cuts likely contributed to this review extension.
https://www.fiercebiotech.com/biotech/praxis-faces-fda-delay-analysts-point-finger-agency-layoffs